Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.3B
153M shares
52-week range
$26.76 – $59.30
81% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
10.4
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
www.tgtherapeutics.comNo one on the platform currently holds TGTX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 340,900 | $11.3M |
| Bridgewater Associatesas of 2026-03-31 | 311,415 | $10.3M |
| Execution date | Ratio |
|---|---|
| 2012-04-30 | 1-for-56.25reverse |
No one on the platform has traded TGTX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 61.9% | — | — | — | ||
| Rev. Growth % | 87.3% | 426.7% | ||||
| Profit Margin % | 72.6% | -2631.1% | -55392.6% | |||
| Free Cash Flow Margin % | -4.1% | -2156.3% | -42665.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +31.9% on the P/E track.
At today's price, your expected annual return is +39.8% on the P/E track.
At today's price, your expected annual return is +47.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $958M | +55.6% | $1.00 | $0.76–$1.44 | 52.9× | 5 |
| 2027 | $1.3B | +37.6% | $2.86 | $2.33–$4.28 | 18.5× | 6 |
| 2028 | $1.6B | +23.2% | $3.67 | $3.14–$4.21 | 14.4× | 6 |
| 2029 | $1.9B | +17.3% | $4.24 | $3.97–$4.64 | 12.5× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $0.31 | $0.05 | -83.6% |
| 2026-05-06 | $0.23 | $0.14 | -39.1% |
| 2026-02-26 | $0.35 | $0.14 | -60.0% |
| 2025-11-03 | $0.24 | $2.43 | +912.5% |
| 2025-08-04 | $0.32 | $0.17 | -46.9% |
| 2025-05-05 | $0.18 | $0.03 | -83.3% |
| 2025-03-03 | $0.08 | $0.15 | +87.5% |
| 2024-11-04 | $0.03 |
| $0.02 |
| -33.3% |
| $5.1B |
| — |
| IMVTImmunovant, Inc. | $37.66 | +0.80% | $7.8B | — |
| KRYSKrystal Biotech, Inc. | $340.03 | -2.01% | $10.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$TGTX Well, I’m sure he learned his lesson and won’t do that again. https://modernity.news/2026/09/15/he-raped-5-women-but-his-life-sentence-is-reduced-to-2-5-years/
View on StockTwits ↗
$TGTX 3 catalyst datat coming up soon. https://www.tgtherapeutics.com/our-pipeline/
View on StockTwits ↗
$TGTX https://x.com/wallstsai/status/2099920436557381898?s=46&t=wy__YpLFjeAlUaQQqzK0mQ
View on StockTwits ↗
$TGTX The ECTRIMS embargo on abstract release is over wed oct 7. If I were short, I would cover before that date.
View on StockTwits ↗
$TGTX Higher interest rates only mean less MS patients, I'm afraid.
View on StockTwits ↗
$IOVA look qt the ride at $TGTX from 8 to now. ererything is possible.
View on StockTwits ↗
Swing — Sep 15 $IBRX $NVAX $TGTX $WMK $ZD - $NVAX and $ZD coiled after a push. Pause on the 20-day, not a fresh base. First poke out of that usually gets sold. - $IBRX is just a tight box. Plenty of energy, no trend to lean on. - $TGTX same squeeze, but the 20-day is cap, not support. That’s the lag. - $WMK coil is real. Grocery tape. Smaller follow-through. Trade the hold after the break, not the pinch.
View on StockTwits ↗
$TGTX A message to rookierider and all other retail long term bulls of TGTX family .Roockie rider is on way from Maine to Florida and displayed the food .To all of you vacationers of TGTX family spend lavishly on your vacation .The simple reason being by the time you all take next vacation possibly you all will have doubled your money on TGTX at the least .
View on StockTwits ↗
$TGTX Regarding seller AND buyer perspectives -- given the sheer volume of CURRENT AND FUTURE revenues on the line, I anticipate a COMPETITIVE buyout, and the players and proposals could be quite different. Examples: Perhaps $SNY submits an all-cash proposal, this could be quick with no anti-trust questions? $BIIB is financially capable of acquiring TGTX, but it cannot do so through a pure cash offer thus perhaps a structured acquisition of debt financing and stock-for-stock equity swaps more complicated but doable? Different tax paths or outcomes for TGTX’s current shareholders – but all good?
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.